FGF21 and metabolic syndrome: The findings of the current study presented herein agree with these data, collectively supporting the hypothesis that serum FGF21 level is likely involved in the process of CAD; the current study provides novel insights into the contribution of FGF21 being independent of such traditional cardiac risk factors as age, hyperglycemia, hypertension, dyslipidemia, and even NAFLD.